|
 Biotechnology
News
How
Prop. 71 came to life (San Diego Union-Tribune)
California Stem Cell Research and Cures Act was work of eclectic
group that included film director, finance expert, Republican and
researcher.
Celebrex
Lifts Heart Attack Risk in Trial (Reuters)
Pfizer Inc. said its popular Celebrex arthritis drug more than doubled
the risk of heart attack in a large cancer-prevention trial, a setback
that comes just weeks after Merck & Co. recalled its similar
Vioxx drug due to heart safety risks.
Pfizer's
Heart Attack (Forbes)
Since Merck's Vioxx was pulled from the market for increasing the
risk of heart attack and stroke in a long-term study, there has
been heated debate over whether other, similar medicines, such as
Pfizer's Celebrex and Bextra, carry similar risks.
California
Stem Cell Initiative Challenged (San Diego Union-Tribune)
Scientists, educators and patient advocates gathered yesterday to
begin figuring out how to distribute $3 billion in state funding
for stem cell research, but it quickly became clear the job will
be controversial.
Biotech
cluster bluster (San Diego Union-Tribune)
San Diego, Bay Area both working to land new institute for stem
cell research.
California's
New Stem-Cell Initiative Is Already Raising Concerns (New York
Times)
As California moves to begin a lushly financed program of embryonic
stem cell research, medical ethicists and other skeptics are concerned
that the $3 billion that state voters approved for the endeavor
could become a bonanza for private profiteers.
California
Stem Cell Project Energizes Other States to Act (Los Angeles
Times)
To keep researchers from being lured away, other funding efforts
are in the works.
Biotech
seek VC alternatives (Bizjournals.com)
Biotechs are forging deals, including partnerships, to find cash.
The
Stem Cell Gold Rush (Wired)
Scientists around the country who study embryonic stem cells may
be mourning four more years of President Bush's restrictive funding
policy, but California scientists are throwing a party, and top
researchers in less-funded states are hoping for invitations.
Schwarzenegger
Backs Stem Cell Study (Los Angeles Times)
Schwarzenegger's backing of a $3-billion stem cell initiative and
a blanket primary goes against his party's positions. The measures
are narrowly ahead in polls. His support could tip the balance.
Genzyme
reports a strong third quarter (Red Herring)
The leader in rare-disease drugs continues to profit in a small
market.
Will
this research pay off? (San Diego Union-Tribune)
Stem cell studies could escalate if investors see profit motive.
HIV
in monkeys 'blocked by drug' (BBC)
Scientists believe they are a step closer to understanding how to
block HIV transmission between men and women.
Death
of a Drug: The Aftermath of Merck's Recall (Knowledge@Wharton)
Less than a week after Merck & Co.'s voluntary withdrawal of
its blockbuster arthritis pain medication Vioxx, the jury is still
out on whether the pharmaceutical giant followed the cardinal rule
of corporate crisis management: "Hide nothing, tell all."
VCs
bankroll bid for stem cell research (San Francisco Business Times)
Venture capitalists appear far more enthusiastic than the biotechnology
industry about a proposition that would create nearly $3 billion
for stem cell research in California over 10 years.
Stem
Cells May Open Some Eyes (Wired)
Scientists have derived retinal cells from embryonic stem cells
for the first time, in a breakthrough that could lead to the first
therapeutic use of the controversial cells.
Boost
for biotech in S.F. (San Francisco Chronicle)
Gladstone Institutes to open Mission Bay research center.
Getting
Out Of Biotech's Second Tier (Washington Post)
If you added all the biotech activity that industry executives and
local officials across the country have forecast for the next decade,
my guess is the industry would be roughly the size of the Chinese
economy.
Go
to Biotechnology News Archive
|
